SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

CAW CRYPTO, also known as crow with knife, is trending as a deflationary meme coin built on multiple chains. Community members are excited about its organic growth and strong cult following, highlighting its presence on Solana, Ethereum, and other networks. The project's burn mechanism and bridge technology are also being actively discussed.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions around meme coins and Phantom Wallet integrations, with the community highlighting specific tokens like $SOLYCAT and $ROSIE. Recent chatter also points to potential growth catalysts like a Fidelity listing and integrations with projects like $IMG, generating optimism within the Solana ecosystem. Some traders are keeping a close eye on technical levels for potential breakouts.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its 10-month anniversary and recent listings, emphasizing its resilience in the meme coin space. Discussions highlight the project's utility, staking on BiFinance, play-to-earn games, and community-driven initiatives. The community is focused on the project's comeback, and building towards new all-time highs.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst a mix of community frustration and hope for future gains, with some users discussing the potential for a price surge while others label it a "scam." The community is closely watching volume and potential catalysts, with some mentioning upcoming events and others expressing concern over stagnant price action compared to other meme coins like $PEPE and $DOGE. Sentiment is divided, with some users remaining bullish and highlighting the strength of the Shiba Inu community.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is trending as it gains traction within the Phantom Wallet community. The community is excited about its potential, referring to it as a "gem" with "rocket vibes" and anticipating a breakout. However, some users are also expressing concerns, labeling it as a potential scam.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential catalysts, including Ripple's recent acquisition and the possibility of XRP ETFs, while also considering the broader market context and potential impact of the government shutdown. Bullish sentiment is fueled by anticipation of increased institutional adoption and reduced circulating supply, though some traders remain cautious, citing historical price patterns and market manipulation. Community members are actively debating potential price targets and the timing of the next significant price movement.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amidst discussions around stablecoin regulation and adoption, with the community actively debating its role in the evolving crypto landscape. Key talking points include Circle's initiatives, such as developer bounties, and the potential impact of upcoming legislation like the GENIUS Act. Furthermore, USDC is being compared to other stablecoins and digital assets like USDT and memecoins, specifically in regards to treasury strategies and market movements.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is experiencing a surge, with community members pointing to insider buying and potential related news as catalysts. Discussions revolve around its low float and the possibility of a short squeeze, leading to speculation about a significant price increase. Some traders, however, are wary of potential dilution impacts, creating a mixed sentiment around Neuphoria Therapeutics.

Jump into the crypto fun with $SOLCAT! Our token features a savvy cat wearing a fabulous Solana hat, offering super cool adventures in the world of meme coins.

CatSolHat

CatSolHat ($SOLCAT) is trending as the community rallies around this Solana-based meme coin. The coin is being touted as 'Solana's sleekest predator' as social media users encourage others to 'join the pride'. It's also being discussed in relation to other meme coins like $PEPE.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors discuss potential catalysts, including upcoming presentations at AASLD and a possible meeting with the FDA, which could lead to a partnership or buyout before year-end. Community members are weighing the potential impact of new data and insider activity, while noting the persistent short interest in the stock. The discussion centers on the potential for Belapectin, GALT's drug, to become a blockbuster treatment for a specific liver condition.

statis crypto Watchlist

Bitcoin

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.
read more...

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Summit Therapeutics Breakthrough with Ivonescimab The recent breakthrough with Summit Therapeutics Ivonescimab (SMT112) reverberated not just in the medical industry but also across the markets. In...

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

FY2028 Earnings Estimate for Nuvectis Pharma, Inc. Issued By Roth Capital (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT  Free Report)  Stock analysts at Roth Capital upped their FY2028 earnings estimates for Nuvectis Pharma in a research note issued on Thursday...

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating...

Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16

Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16...

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the...

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Nuvectis Pharma Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$6.25
Beta	0.74
Avg. Volume	91,342.90
PE Ratio	-5.51

52-Week High	$11.80
52-Week Low	$4.44
Market Capitalization	$157.83M
EPS (Annual)	-$1.11
Price to Book	8.77
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NVCT
Nuvectis Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVCT News

NVCTNuvectis Pharma Inc